Publications

 

1. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Moss ML, Rasmussen FH. Anal Biochem. 2007 Jul 15;366(2):144-8.
2. Potential of Fluorescent Metalloproteinase Substrates for Cancer Detection. Roopali Roy, et al. Clin Biochem. Dec. 2011; 44(17-18): 1434-1439.
3. Multiplexed protease activity assay for low-volume clinical samples using droplet-based microfluidics and its application to endometriosis. Chen CH, et al. J Am Chem Soc. 2013 Feb 6;135(5):1645-8. doi: 10.1021/ja307866z
4. Fluorescent substrates useful as high-throughput screening tools for ADAM9. Moss ML et al. Comb Chem High Throughput Screen. 2010 May;13(4):358-65.
5. High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation. Wu L, et al. Integr Biol(Camb). 2015 May;7(5):513-24. doi: 10.1039/c5ib00019j. Epub 2015 Apr 2.
6. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Caescu CL, et al. Biochem J. 2009 Oct 23;424(1):79-88. doi: 10.1042/BJ20090549.
7. Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer. Ouyang M, et al. Cancer Res. 2010 Mar 15;70(6):2204-12. doi: 10.1158/0008-5472.CAN-09-3698.
8. Proteolytic Activity Matrix Analysis (PrAMA) for Simultaneous Determination of Multiple Protease Activities. Miller MA, et al. Integr Biol (Camb). 2011 Apr: 3(4): 422-438.
9. ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein. Moss ML, et al. J Biol Chem. 2011 Nov 25;286(47):40443-51. doi: 10.1074/jbc.M111.280495.
10. ADAM8 as a drug target in pancreatic cancer. Schlomann, U, et al. Nat Commun 2015 Jan 28;6:6175. doi: 10.1038/ncomms7175.
11. A colorimetric-based amplification system for proteinases including MMP2 and ADAM8. Moss ML, et al. Anal Biochem. 2015 May 27;484:75-81. doi: 10.1016/j.ab.2015.05.011.